Teicoplanin-A New Use for an Old Drug in the COVID-19 Era?

Teicoplanin is an Antibiotic that has been actively used in medical practice since 1986 to treat serious Gram-positive Bacterial infections. Due to its efficiency and low cytotoxicity, teicoplanin has also been used for patients with complications, including pediatric and immunocompromised patients. Although teicoplanin is accepted as an Antibacterial drug, its action against RNA viruses, including SARS-CoV2, has been proven in vitro. Here, we provide a thorough overview of teicoplanin usage in medicine, based on the current literature. We summarize Infection sites treated with teicoplanin, concentrations of the Antibiotic in different organs, and side effects. Finally, we summarize all available data about the Antiviral activity of teicoplanin. We believe that, due to the extensive experience of teicoplanin usage in clinical settings to treat Bacterial infections and its demonstrated activity against SARS-CoV2, teicoplanin could become a drug of choice in the treatment of COVID-19 patients. Teicoplanin stops the replication of the virus and at the same time avoids the development of Gram-positive Bacterial co-infections.

COVID-19; SARS-CoV2; antibiotic; bacteria; co-infection; dalbavancin; lipoglycopeptide antibiotic; teicoplanin.